refractory lymphoma

Following Kite Pharma's Positive Top-Line Data, Focus Turns To Commercial Outlook
Yahoo/Benzinga
Sat, 10/8/16 - 03:46 pm
Kite Pharma
clinical trials
KTE-C19
CAR-T
refractory lymphoma